Abstract
Alogliptin is a new gliptin registered for use in the Czech Republic. Published studies have shown its safety and efficacy.
The safety of alogliptin from the cardiovascular viewpoint has been shown in the EXAMINE trial. Alogliptin is registered for the therapy of type 2 diabetes as part of dual combinations with metformin, a sulfonylurea, thiazolidindiones, or insulin, or in the triple combination with metformin and thiazolidindiones or insulin.
Recommended basic dose is 25 mg once daily.